在心力衰竭和减少喷射分数的Vericiguat和死亡率:VICTOR试验
Javed Butler1,2, Francesco Fioretti2, Ciaran J McMullan3
1Department of Medicine, University of Mississippi, Jackson, MS, USA.
European heart journal
|August 30, 2025
概括
在心力衰竭患者中,Vericiguat显著降低了心血管和全因死亡率 (HFrEF). 这项对VICTOR试验的分析表明,
科学领域:
- 心脏病学
- 药理学
- 临床试验
背景情况:
- 在VICTOR试验 (NCT05093933) 中,对心力衰竭患者进行了评估.
- 虽然主要复合终点是中性的,但该试验的动力可以独立评估心血管死亡.
- 这项研究详细分析了 vericiguat 对死亡率的影响.
研究的目的:
- 详细分析了多西瓜特对心血管死亡率的影响.
- 评估放心剂对所有死因,心脏突然死亡和心力衰竭相关死亡的影响.
- 评估不同患者小组和基线特征的死亡益处.
主要方法:
- 这是一项双盲,安慰剂对照的随机试验,涉及6105名患有HFrEF的门诊患者.
- 患者被随机分为接受 vericiguat 或安慰剂.
- 这项分析的主要结局是心血管死亡的预规定的二次终点;所有原因,突然心脏和与HF相关的死亡也被评估.
主要成果:
- 与安慰剂相比,Vericiguat显著降低了心血管死亡率 (HR 0. 83,P=0. 020) 和所有原因死亡率 (HR 0. 84,P=0. 015).
- 心脏突然死亡率 (HR 0.75,P=0.042) 和与心脏衰竭相关的死亡率 (HR 0.71,P=0.016) 也较低.
- 这些死亡益处在包括基线治疗和N-终端亲B型尿酸水平在内的各个亚组中一致.
结论:
- 在VICTOR试验中,Vericiguat在临床上显著降低了心血管死亡率.
- 在门诊治疗的HFrEF患者中,Vericiguat与全因死亡率的显著降低有关.
- 这些研究结果支持多西瓜特在改善特定心力衰竭患者的存活率方面的作用.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.4K
相关概念视频
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717